Intra-Cellular Therapies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intra-Cellular Therapies, Inc.
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.